Business Description
4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company founded in 2018 that develops innovative DNA-based treatments for cancer and genetic disorders. Its pipeline features lead candidate FDMT-101 alongside additional programs such as FDMT-102 and FDMT-103, supported by a proprietary delivery platform. Under the leadership of CEO Dr. Michael Hauser and CFO Amanda Clarke, the company has raised over $50 million through strategic collaborations and milestone-based agreements. With several Phase I/II trials on the horizon, 4D Molecular Therapeutics is positioned as a promising emerging competitor in the biotech sphere.
Everything on 4D Molecular Therapeutics Inc.
Revenue (FY2025)
$85M
YoY growth
+230194.6%
Operating margin
-187.2%
Direction
Expanding
Gross margin
100.0%
Net margin
-164.4%
David Kirn, M.D. — Co-Founder, President, Chief Executive Officer and Director
View full profile ↗
John F. Milligan, Ph.D. — Director and Executive Chairman
View full profile ↗
Jacob Chacko, M.D., MBA — Director
View full profile ↗
Susannah Gray, MBA — Director
View full profile ↗
Charles P. Theuer, M.D., Ph.D. — Director
View full profile ↗
Nancy Miller-Rich — Director
View full profile ↗
Shawn Cline Tomasello, MBA — Director
View full profile ↗
Glenn Sblendorio — Director
View full profile ↗
Kristian Humer — Chief Financial Officer
View full profile ↗
Christopher Simms — Chief Commercial and Business Officer
View full profile ↗
Scott Bizily, J.D., Ph.D. — Chief Legal Officer and Corporate Secretary
View full profile ↗
Ashoo Gupta — Vice President, Finance and Controller
View full profile ↗
Fariborz Kamal, Ph.D. — Former President and Chief Operating Officer; Chief Technical Advisor
View full profile ↗
Noriyuki Kasahara, M.D., Ph.D. — Chief Scientific Officer; former Director
View full profile ↗
David Schaffer, Ph.D. — Co-Founder and Chief Scientific Advisor; former Director
View full profile ↗
Uneek Mehra — Former Chief Financial and Business Officer
View full profile ↗
August J. Moretti — Former Chief Financial Officer
View full profile ↗
Robert Fishman, M.D. — Former Chief Medical Officer
View full profile ↗
Named Competitors
AbbVie Inc.REGENXBIO Inc.Adverum Biotechnologies Inc.Eli Lilly and CompanyEyePoint Inc.Ocular Therapeutix Inc.Kodiak Sciences Inc.Merck & Company Inc.Regeneron Pharmaceuticals Inc.RocheApellis Pharmaceuticals Inc.Astellas Pharma Inc.
+6 more